·

On July 13, 2015, the company announced that its Phase 3 ENSPIRIT trial evaluating custirsen for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) is continuing as planned per the recommendation of an Independent Data Monitoring Committee (IDMC). This decision was based upon completion of the second and final planned interim futility analysis that included a more rigorous evaluation for determining futility in achieving a survival benefit associated with custirsen in NSCLC. Based on current enrollment projections, the company believes final survival results could be available in the second half of 2016.

·

On June 10, 2015, OncoGenex announced that the U.S. Food and Drug Administration (FDA) has agreed to the company's proposed amendment to the Phase 3 AFFINITY protocol and statistical analysis plan. The proposed amendment includes the addition of a co-primary survival objective designed to prospectively evaluate the survival benefit of custirsen in men who are at increased risk for poor outcomes when treated with cabazitaxel for metastatic castrate-resistant prostate cancer (CRPC). Patients at risk for poor outcomes will be identified as having two or more of five common risk factors. In addition, OncoGenex and the FDA agreed that an interim analysis will occur for the entire study population when the final analysis for the poor prognosis subpopulation occurs. Advice from the European Medicines Agency through its Scientific Review process will be completed prior to finalizing the protocol amendment.  Subject to finalizing the pending protocol amendment, timing for the final analysis of the poor prognosis subpopulation is projected to occur by the end of 2015, while the final analysis for the entire study population is projected to occur in the second half of 2016.

·

On May 30, 2015, the company announced that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic CRPC who were at risk for poor outcomes. The analysis, exploring the effect of clusterin inhibition in men at risk for poor outcomes, showed that over 40% of men in the trial had at least two of five common risk factors for poor prognosis.  In these men, the analysis found a 27% lower risk of death when custirsen was used in combination with first-line docetaxel compared to docetaxel alone. These results were presented at the 51st Annual Meeting of the American Society of Clinical Oncology in Chicago.

·

Investigators from the Phase 2 Borealis-1 trial™ presented results from an exploratory analysis  that showed metastatic bladder cancer patients with poor prognostic features (KPS, liver involvement, low hemoglobin and high alkaline phosphatase) benefited from apatorsen 600mg added to first-line chemotherapy (OS HR = 0.72) compared to chemotherapy alone.  Patients in the trial with a Karnofsky Performance Status (KPS) of 80% or less, a common indicator of poor

prognosis, experienced a 50% reduction in risk of death with the addition of apatorsen therapy (OS HR = 0.50). These results were presented in an oral session on June 1, 2015 at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

·

Revenue for the three and six months ended June 30, 2015 decreased to $4.0 million and $5.4 million, respectively, from $4.9 million and $16.7 million for the three and six months ended June 30, 2014, respectively.

·

Total operating expenses for the three and six months ended June 30, 2015 were $9.6 million and $16.0 million, respectively, compared to $12.6 million and $32.2 million for the three and six months ended June 30, 2014, respectively.

·

Net loss for the three and six months ended June 30, 2015 was $6.0 million, or $0.26 per dilluted common share, and $10.5 million, or $0.46 per dilluted common share, respectively, compared with $7.0 million, or $0.47 per diluted common share, and $15.7 million, or $1.05 per dilluted common share, respectively, for the three and six months ended June 30, 2014.

·

As of June 30, 2015, cash, cash equivalents and short-term investments increased to $60.2 million from $47.1 million as of December 31, 2014.

·

Subsequent to June 30, 2015, the company raised $14.7 million from the sale of common stock to Lincoln Park Capital, LLC under the terms of the share purchase agreement. As of August 13, 2015, no further amounts remained available for sale under this offering program.

·

Based on current expectations, the company believes that these resources, in addition to the amounts received from the sale of common stock to Lincoln Park Capital, LLC in the third quarter of 2015 will be sufficient to fund its currently planned operations late into the fourth quarter of 2016, which may include:

o

announcement of final results of the poor prognosis subpopulation in the Phase 3 AFFINITY prostate cancer trial by the end of 2015 and final analysis for the entire study population in the second half of 2016, depending on timing of the event-driven final analysis and subject to completion and submission of the proposed protocol amendment;

o

announcement of final survival results in the Phase 3 ENSPIRIT lung cancer trial expected in the second half of 2016;

o

completion of enrollment in the Phase 2 Borealis-2™ bladder cancer trial expected to occur in the third quarter of 2015;

o

announcement of the Phase 2 Rainier™ pancreatic cancer trial results expected by the end of 2015;

o

announcement of the Phase 2 Spruce™ lung cancer trial results expected in the first half of 2016;

o

announcement of the Phase 2 Pacific™ prostate cancer trial preliminary results expected in 2016; and

o

completion of enrollment in the Phase 2 Cedar™ lung cancer trial expected in 2016.

·

As of August 13, 2015, OncoGenex had 29,791,776 shares outstanding.

Consolidated Statements of Loss

(In thousands, except per share and share data)

(unaudited)

Three months ended June 30,

Six months ended June 30,

2015

2014

2015

2014

Collaboration revenue

$

4,025

$

4,929

$

5,399

$

16,660

Operating expenses:

  Research and development

6,545

9,883

10,217

26,786

  General and administrative

3,067

2,676

5,765

5,433

    Total operating expenses

9,612

12,559

15,982

32,219

Loss from operations

(5,587

)

(7,630

)

(10,583

)

(15,559

)

  Other income (expense)

(423

)

615

56

(92

)

Net loss

$

(6,010

)

$

(7,015

)

$

(10,527

)

$

(15,651

)

Basic and diluted net loss per share

$

(0.26

)

$

(0.47

)

$

(0.46

)

$

(1.05

)

Weighted average number of basic and diluted common shares

23,484,944

14,987,706

23,072,773

14,855,338

Consolidated Balance Sheets

(In thousands)

June 30,

December 31,

2015

2014

(unaudited)

Assets:

  Cash, cash equivalents, short term investments and restricted cash

$

60,376

$

47,308

  Interest receivable

76

113

  Amounts receivable

149

5,676

  Prepaid expenses and other current assets

2,336

2,664

  Property, equipment and other assets

419

530

Total assets

$

63,356

$

56,291

Liabilities and stockholders' equity:

  Accounts payable and accrued liabilities

$

12,986

$

15,730

  Current portion of long-tem obligations

54

236

  Warrant liability

2,967

3,002

  Lease termination liability

1,250

3,250

  Deferred collaboration revenue

17,778

-

  Long term liabilities

130

14

  Stockholders' equity

28,191

34,059

Total liabilities and stockholders' equity

$

63,356

$

56,291